PROCESS VALIDATION SERVICE BUSINESS PLAN

I. Executive Summary

Company Description

Veridian Validation Group is a U.S.-based consulting firm launching in 2026 that serves regulated manufacturing—pharmaceuticals, biotechnology, and medical devices. The name Veridian signals precision and growth: verde (green) for safety and ridian for rigor. We provide end-to-end process validation services: protocol development, qualification testing, statistical validation, data integrity reviews, and FDA/cGMP compliance reporting. Our team of senior engineers and validation specialists uses a modern, data-driven toolset to reduce validation cycle time and documentation risk. One-line: we make regulated production lines compliant and audit-ready, faster and with less rework.

We target mid-size to large manufacturers with new product introductions or facility changes in the U.S. market. Short-term goals: win three anchor contracts and achieve $2.5M ARR in year one. Long-term goals: scale to 30 consultants, expand into continuous monitoring services, and reach $18M ARR by year five. What sets us apart: specialist-only focus on process validation, senior-led project teams, measurable validation KPIs, and fixed-fee bundles that align incentives with client timelines. One-line: we deliver measurable compliance outcomes tied to client launch dates.

Problem

US pharmaceutical, biotechnology, and medical device manufacturers face extreme regulatory pressure to meet FDA and current Good Manufacturing Practice (cGMP) standards; validation failures cause production stoppages, shipment delays, costly recalls, heavy fines, and lasting loss of market trust. Validation failures stop production and threaten business survival.

Small and mid-sized firms routinely lack in-house technical expertise to manage complex validation lifecycles, creating an ongoing gap for specialized oversight. Existing options—sporadic internal hires, generalist consultants, or delayed contract services—do not consistently deliver the continuous, data-driven validation programs required to keep regulated production lines compliant and operational. A focused service that provides dedicated engineers and validation specialists is therefore necessary. One-liner: manufacturers need reliable, expert validation oversight to avoid stoppages and regulatory harm.

Solution

US life-sciences manufacturers face high regulatory and financial risk from complex FDA process-validation requirements and frequent internal skill gaps. We provide third-party manufacturing process validation services—designing and executing Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) and delivering audit-ready documentation and traceable records—so clients meet cGMP standards, avoid delays and recalls, and hand off validation deliverables to their quality teams.

One line: We eliminate validation risk by delivering end-to-end IQ/OQ/PQ and audit-ready records that keep production compliant and launch-ready.

Mission Statement

To provide the most precise and reliable manufacturing process validation services in the US life sciences industry, ensuring our clients achieve seamless regulatory compliance and produce the highest quality products. We de-risk the manufacturing lifecycle through specialized expertise, modern technology, and a commitment to operational excellence. We prioritize customer satisfaction, continuous innovation, and responsible practices that support safe, effective therapies for patients.

Key Success Factors

Our success rests on a singular technical focus and repeatable operational practices that deliver faster, cost-effective, audit-ready process validation.

• Exclusive focus on process validation: deeper technical expertise than generalist firms.
• Senior Validation Engineer team: qualified staff with a competitive salary structure to ensure low turnover.
• Data-driven methods and proprietary SOP templates: faster delivery and lower client costs.
• Strategic partnerships: equipment suppliers and industry associations provide consistent, high-quality leads.
• Audit-ready documentation: clients can face FDA scrutiny with confidence.

Financial Summary

The firm forecasts rapid growth from startup to sustained profitability driven by a shift to higher-value validation and remediation services.

Financial requirements: minimum cash reserve $535,000; breakeven expected Jul-2026 (7 months); payback in 23 months. Anticipated returns: IRR 7.43% and ROE 7.5%.

Overall outlook: profitable by mid-2026 with expanding margins and growing cash generation through 2030.

Funding Requirements

We need USD 928,600 to cover initial capital, working capital, first-year insurance, and 2026 marketing to reach USD 1,327,000 Year 1 revenue, scaling to USD 7,673,000 by 2030; break-even is projected July 2026 (month 7), EBITDA grows from USD 35,000 Year 1 to USD 3,307,000 Year 5, with an IRR of 7.43% and ROE of 7.5%.